The firm is focused on helping pharma characterize response and resistance to their drugs, with the hope of getting a companion diagnostic approval.

Cancer care is becoming more targeted with the development of therapies that address specific genetic signatures. Before such drugs are used, a test identifies whether a patient’s cancer matches an ...

Genes include key targets for next generation precision medicines, such as NECTIN4, B7H4, HER3, DLL3, MUC1, MET, and HER2 and master regulators of transcription, such as AR, ER, FOXA1, ASCL1, and ...

Rehan Verjee is no stranger to making medicines, having taken several candidates through FDA approvals as the former president of EMD Serono and global head of the Innovative Medicine Franchises at ...

A new spinout from Dana-Farber Cancer Institute aims to deliver a series of blood tests aimed not only at directing patients to precision tumor treatments, but also at assisting drug developers in ...